TriSalus Life Sciences, Inc. — Director's Dealing 2025

Feb 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TriSalus Life Sciences, Inc. (TLSI)
CIK: 0001826667
Period of Report: 2025-02-10

Reporting Person: Wahlstrom Mats (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-10	Series A Convertible Preferred Stock	$5.277	J	44750	Acquired		Common Stock (44750)	Indirect

Footnotes

F1: The conversion price (the "Conversion Price") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023.

F2: Effective February 10, 2025, the Conversion Price of the 50,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock.

F3: After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 94,750 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election.

F4: All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

F5: Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset.

F6: The Reporting Person shares voting and investment discretion with his spouse with respect to the shares held directly by Leonard Capital LLC.